Measuring dopamine synaptic transmission with molecular imaging and pharmacological challenges: The state of the art

Neuromethods

Volumn 71, Issue , 2012, Pages 163-203

  Laruelle, Marc ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Fallypride; FLB 457; IBZM; Internalization; MNPA; NPA; PET, SPECT; PHNO; Raclopride; Spiperone

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; BRAIN RECEPTOR; COCAINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; FALLYPRIDE; FALLYPRIDE F 18; FLESINOXAN; IOLOPRIDE; IOLOPRIDE I 123; ISOREMOXIPRIDE; KETAMINE; METHYLPHENIDATE; MODAFINIL; NEURORECEPTOR; PLACEBO; QUINPIROLE; RACLOPRIDE; RACLOPRIDE C 11; RADIOLIGAND; RESERPINE; SEROTONIN 2A RECEPTOR; SPIPERONE DERIVATIVE; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANOXERINE;

ARTICLE; BINDING AFFINITY; BRAIN RADIOGRAPHY; CONTINUOUS INFUSION; DOPAMINERGIC TRANSMISSION; HUMAN; IN VIVO STUDY; MENTAL DISEASE; MICRODIALYSIS; MOLECULAR IMAGING; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIMATE; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR OCCUPANCY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84867554970     PISSN: 08932336     EISSN: 19406045     Source Type: Book Series    
DOI: 10.1007/7657-2012-45     Document Type: Article

References (250)

1. Friedman AM et al (1984) Measurements in vivo of parameters of the dopamine system. Ann Neurol 15(Suppl):S66-76
2. Leysen JE, Gommeren W, Laduron PM (1978) Spiperone: a ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding. Biochem Pharmacol 27(3):307-16
3. Lyon RA et al (1986) 3 H-3-N-methylspiperone labels D2 dopamine receptors in basal ganglia and S2 serotonin receptors in cerebral cortex. J Neurosci 6(10):2941-9
4. Wagner H Jr et al (1983) Imaging dopamine receptors in the human brain by positron tomography. Science 221(4617):1264-6
5. Ehrin E et al (1985) Preparation of 11 Clabelled Raclopride, a new potent dopamine receptor antagonist: preliminary PET studies of cerebral dopamine receptors in the monkey. Int J Appl Radiat Isot 36(4):269-73
6. Kohler C et al (1985) Specific in vitro and in vivo binding of 3 H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34(13):2251-9
7. Kung HF et al (1988) Preparation and biodistribution of [125I]IBZM: a potential CNS D- 2 dopamine receptor imaging agent. Nucl Med Biol 15(2):195-201
8. Innis RB et al (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-39
9. Dewey SL et al (1990) Positron emission tomography (PET) studies of dopamine/cholinergic interaction in the baboon brain. Synapse 6:321-327
10. Logan J et al (1991) Effects of endogenous dopamine on measures of [18 F]N-methylspiroperidol binding in the basal ganglia: comparison of simulations and experimental results from PET studies in baboons. Synapse 9(3):195-207
11. Dewey SL et al (1991) Amphetamine induced decrease in [18 F]-N-methylspiperidol binding in the baboon brain using positron emission tomography (PET). Synapse 7:324-327
12. Hartvig P et al (1997) Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography. J Neural Transm 104(4-5):329-339
13. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20(3):423-51
14. Villemagne VL et al (1999) GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C] raclopride continuous infusion PET scans. Synapse 33(4):268-273
15. Dewey SL et al (1993) Striatal binding of the PET ligand 11 C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13(4):350-6
16. Carson RE et al (1997) Quantification of amphetamine-induced changes in [C-11] raclopride binding with continuous infusion. J Cereb Blood Flow Metab 17(4):437-447
17. Ginovart N et al (1998) Effect of anesthetics and evoked dopamine release on [11 C]raclopride binding in the cat striatum. Neuroimage 7:A7
18. Ginovart N et al (1999) Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates. Synapse 31 (2):154-62
19. Volkow ND et al (1999) Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. Synapse 31(1):59-66
20. Abi-Dargham A et al (1999) PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11 C] NNC 756. Synapse 32(2):93-109
21. Price J et al (1998) PET measurement of endogenous neurotransmitter activity using high and low affinity radiotracers. In: Carson R, Daube-Witherspoon ME, Herscovitch P (eds) Quantitative functional brain imaging with positron emission tomography. Academic, San Diego, pp 441-448
22. Ginovart N et al (1997) Effect of reserpineinduced depletion of synaptic dopamine on [C-11]raclopride binding to D-2-dopamine receptors in the monkey brain. Synapse 25 (4):321-325
23. Gatley SJ et al (1995) Sensitivity of striatal [11 C]cocaine binding to decreases in synaptic dopamine. Synapse 20(2):137-44
24. Innis RB et al (1992) Amphetaminestimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in non-human primates. Synapse 10:177-184
25. Laruelle M et al (1997) Microdialysis and SPECT measurements of amphetamineinduced dopamine release in nonhuman primates. Synapse 25:1-14
26. Mach RH et al (1997) Use of positron emission tomography to study the dynamics of psychostimulant-induced dopamine release. Pharmacol Biochem Behav 57(3):477-486
27. Kessler RM et al (1993) Evaluation of 5- [18 F]fluoropropylepidepride as a potential PET radioligand for imaging dopamine D2 receptors. Synapse 15(3):169-76
28. Mukherjee J et al (1997) Evaluation of damphetamine effects on the binding of dopamine D-2 receptor radioligand, F-18-fallypride in nonhuman primates using positron emission tomography. Synapse 27(1):1-13
29. Narendran R et al (2005) Measurement of the proportion of D2 receptors configured in state of high affinity for agonists in vivo: a positron emission tomography study using [11 C]N-propyl-norapomorphine and [11 C]raclopride in baboons. J Pharmacol Exp Ther 315(1):80-90
30. Mukherjee J et al (2005) Measurement of d-amphetamine-induced effects on the binding of dopamine D-2/D-3 receptor radioligand, 18 F-fallypride in extrastriatal brain regions in non-human primates using PET. Brain Res 1032(1-2):77-84
31. Chou YH, Halldin C, Farde L (2000) Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: a PET study. Synapse 38(2):138-43
32. Narendran R et al (2006) Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11 C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 60(7):485-95
33. Narendran R et al (2004) In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11 C]propyl-norapomorphine ([11 C]NPA) with the D2 receptor antagonist radiotracer [11 C]-raclopride. Synapse 52 (3):188-208
34. Seneca N et al (2006) Effect of amphetamine on dopamine D2 receptor binding in nonhuman primate brain: a comparison of the agonist radioligand [11 C]MNPA and antagonist [11 C]raclopride. Synapse 59(5):260-9
35. Ginovart N et al (2006) Binding characteristics and sensitivity to endogenous dopamine of [11 C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 97(4):1089-103
36. Tokunaga M et al (2009) Neuroimaging and physiological evidence for involvement of glutamatergic transmission in regulation of the striatal dopaminergic system. J Neurosci 29 (6):1887-96
37. Farde L et al (1992) Positron emission tomography analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49:538-544
38. Volkow ND et al (1994) Imaging endogenous dopamine competition with [11 C]raclopride in the human brain. Synapse 16:255-262
39. Laruelle M et al (1995) SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36:1182-1190
40. Booij J et al (1997) Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 24(6):674-677
41. Breier A et al (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94 (6):2569-2574
42. Martinez D et al (2003) Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23(3):285-300
43. Cardenas L et al (2004) Oral D-amphetamine causes prolonged displacement of [11 C] raclopride as measured by PET. Synapse 51 (1):27-31
44. LeytonMet al (2002) Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11 C] raclopride study in healthy men. Neuropsychopharmacology 27(6):1027-35
45. Drevets WC et al (2001) Amphetamineinduced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 49(2):81-96
46. Watabe H et al (2000) Measurement of dopamine release with continuous infusion of [11 C]raclopride: optimization and signalto- noise considerations. J Nucl Med 41 (3):522-30
47. Carson RE et al (2001) Amphetamineinduced dopamine release: duration of action assessed with [11 C]raclopride in anesthetized monkeys. In: Gjedde A et al (eds) Physiological imaging of the brain with PET. Academic, San Diego, CA
48. Oswald LM et al (2005) Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacology 30(4):821-32
49. Narendran R et al (2010) A comparative evaluation of the dopamine D(2/3) agonist radiotracer [11 C](-)-N-propyl-norapomorphine and antagonist [11 C]raclopride to measure amphetamine-induced dopamine release in the human striatum. J Pharmacol Exp Ther 333(2):533-9
50. Oswald LM et al (2007) Impulsivity and chronic stress are associated with amphetamine-induced striatal dopamine release. Neuroimage 36(1):153-66
51. Volkow ND et al (2002) Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 43(3):181-7
52. Clatworthy PL et al (2009) Dopamine release in dissociable striatal subregions predicts the different effects of oral methylphenidate on reversal learning and spatial working memory. J Neurosci 29(15):4690-6
53. Munro CA et al (2006) Sex differences in striatal dopamine release in healthy adults. Biol Psychiatry 59(10):966-74
54. Boileau I, et al. (2003) Sensitization to psychostimulants: a PET/[11 C]-Raclopride study in healthy volunteers. ACNP Annual Meting Abstracts
55. Kegeles LS et al (1999) Stability of [123I] IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans. Synapse 31(4):302-8
56. Abi-Dargham A et al (2003) Dopamine mediation of positive reinforcing effects of amphetamine in stimulant naive healthy volunteers: results from a large cohort. Eur Neuropsychopharmacol 13(6):459-68
57. Udo de Haes JI et al (2005) Assessment of methylphenidate-induced changes in binding of continuously infused [(11)C]-raclopride in healthy human subjects: correlation with subjective effects. Psychopharmacology (Berl) 183(3):322-30
58. Schlaepfer TE et al (1997) PET study of competition between intravenous cocaine and [C-11]raclopride at dopamine receptors in human subjects. Am J Psychiatry 154 (9):1209-1213
59. Leyton M et al (2004) Decreasing amphetamine-induced dopamine release by acute phenylalanine/tyrosine depletion: A PET/[11 C]raclopride study in healthy men. Neuropsychopharmacology 29(2):427-32
60. Cox SM et al (2011) Effects of lowered serotonin transmission on cocaine-induced striatal dopamine response: PET [11 C]raclopride study in humans. Br J Psychiatry 199:391-397
61. Cox SM et al (2009) Striatal dopamine responses to intranasal cocaine selfadministration in humans. Biol Psychiatry 65 (10):846-50
62. Brody AL et al (2004) Smoking-induced ventral striatum dopamine release. Am J Psychiatry 161(7):1211-8
63. Montgomery AJ et al (2007) The effect of nicotine on striatal dopamine release in man: A [11 C]raclopride PET study. Synapse 61 (8):637-45
64. Brody AL et al (2009) Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette. Neuropsychopharmacology 34(2):282-9
65. Takahashi H et al (2008) Enhanced dopamine release by nicotine in cigarette smokers: a double-blind, randomized, placebo-controlled pilot study. Int J Neuropsychopharmacol 11 (3):413-7
66. Barrett SP et al (2004) The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11 C]raclopride. Synapse 54(2):65-71
67. Marenco S et al (2004) Nicotine-induced dopamine release in primates measured with [11 C]raclopride PET. Neuropsychopharmacology 29(2):259-68
68. Daglish MR et al (2008) Brain dopamine response in human opioid addiction. Br J Psychiatry 193(1):65-72
69. Boileau I et al (2003) Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 49(4):226-31
70. Yoder KK et al (2007) Heterogeneous effects of alcohol on dopamine release in the striatum: a PET study. Alcohol Clin Exp Res 31 (6):965-73
71. Urban NB et al (2010) Sex differences in striatal dopamine release in young adults after oral alcohol challenge: a positron emission tomography imaging study with [(1)(1) C]raclopride. Biol Psychiatry 68(8):689-96
72. Stokes PR et al (2009) Can recreational doses of THC produce significant dopamine release in the human striatum? Neuroimage 48 (1):186-90
73. Egerton A et al (2009) Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: an [11 C]raclopride PET study. Neuroimage 50(1):260-6
74. Volkow ND et al (2009) Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 301(11):1148-54
75. Bantick RA, De Vries MH, Grasby PM (2005) The effect of a 5-HT1A receptor agonist on striatal dopamine release. Synapse 57 (2):67-75
76. Smith GS et al (1998) Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11 C-raclopride in normal human subjects. Neuropsychopharmacology 18(1):18-25
77. Breier A et al (1998) Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29(2):142-7
78. Vollenweider FX et al (2000) Effects of (S)-ketamine on striatal dopamine: a [11 C] raclopride PET study of a model psychosis in humans. J Psychiatr Res 34(1):35-43
79. Kegeles LS et al (2002) NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans. Synapse 43(1):19-29
80. Aalto S et al (2002) Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology (Berl) 164(4):401-6
81. Koepp MJ et al (1998) Evidence for striatal dopamine release during a video game. Nature 393(6682):266-8
82. Goerendt IK et al (2003) Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. Brain 126(Pt 2):312-25
83. Ouchi Y et al (2002) Effect of simple motor performance on regional dopamine release in the striatum in Parkinson disease patients and healthy subjects: a positron emission tomography study. J Cereb Blood Flow Metab 22 (6):746-52
84. de la Fuente-Fernandez R et al (2001) Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293(5532):1164-6
85. Boileau I et al (2007) Conditioned dopamine release in humans: a positron emission tomography [11 C]raclopride study with amphetamine. J Neurosci 27(15):3998-4003
86. Scott DJ et al (2007) Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 55 (2):325-36
87. Scott DJ et al (2008) Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry 65(2):220-31
88. Volkow ND et al (2002) Nonhedonic food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse 44(3):175-80
89. Volkow ND et al (2003) Brain dopamine is associated with eating behaviors in humans. Int J Eat Disord 33(2):136-42
90. Small DM, Jones-Gotman M, Dagher A (2003) Feeding-induced dopamine release in dorsal striatum correlates with meal pleasantness ratings in healthy human volunteers. Neuroimage 19(4):1709-15
91. Scott DJ et al (2007) Time-course of change in [11 C]carfentanil and [11 C]raclopride binding potential after a nonpharmacological challenge. Synapse 61(9):707-14
92. Montgomery AJ, Mehta MA, Grasby PM (2006) Is psychological stress in man associated with increased striatal dopamine levels?: A [11 C]raclopride PET study. Synapse 60 (2):124-31
93. Soliman A et al (2008) Stress-induced dopamine release in humans at risk of psychosis: a [11 C]raclopride PET study. Neuropsychopharmacology 33(8):2033-41
94. Pruessner JC et al (2004) Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11 C]raclopride. J Neurosci 24 (11):2825-31
95. Zald DH et al (2004) Dopamine transmission in the human striatum during monetary reward tasks. J Neurosci 24(17):4105-12
96. Wong DF et al (2006) Increased occupancy of dopamine receptors in human striatum during cue-elicited cocaine craving. Neuropsychopharmacology 31(12):2716-27
97. Volkow ND et al (2006) Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci 26 (24):6583-8
98. Salimpoor VN et al (2011) Anatomically distinct dopamine release during anticipation and experience of peak emotion to music. Nat Neurosci 14(2):257-62
99. Volkow ND et al (2009) Hyperstimulation of striatal D2 receptors with sleep deprivation: Implications for cognitive impairment. Neuroimage 45(4):1232-40
100. Volkow ND et al (2008) Sleep deprivation decreases binding of [11 C]raclopride to dopamine D2/D3 receptors in the human brain. J Neurosci 28(34):8454-61
101. Strafella AP et al (2003) Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex. Brain 126(Pt 12):2609-15
102. Strafella AP et al (2001) Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. J Neurosci 21(15):157
103. LaruelleMet al (1997) Imaging D-2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17 (3):162-174
104. Verhoeff NP et al (2003) Effects of catecholamine depletion on D(2) receptor binding, mood, and attentiveness in humans: a replication study. Pharmacol Biochem Behav 74 (2):425-432
105. Verhoeff NP et al (2002) Dopamine depletion results in increased neostriatal D(2), but not D(1), receptor binding in humans. Mol Psychiatry 7(3):233
106. Verhoeff NP et al (2001) A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects. Neuropsychopharmacology 25:213-223
107. Kegeles LS et al (2010) Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 67(3):231-9
108. Abi-Dargham A et al (2000) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97(14):8104-8109
109. Slifstein M et al (2004) Effect of amphetamine on [(18)F]fallypride in vivo binding to D(2) receptors in striatal and extrastriatal regions of the primate brain: Single bolus and bolus plus constant infusion studies. Synapse 54(1):46-63
110. Cropley VL et al (2008) Small effect of dopamine release and no effect of dopamine depletion on [18 F]fallypride binding in healthy humans. Synapse 62(6):399-408
111. Riccardi P et al (2006) Amphetamineinduced displacement of [18 F] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacology 31(5):1016-26
112. Narendran R et al (2009) Positron emission tomography imaging of amphetamineinduced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11 C]FLB 457 and [11 C]fallypride. Synapse 63 (6):447-61
113. Slifstein M et al (2009) Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride. Synapse 64(5):350-62
114. Narendran R et al (2010) Positron emission tomography imaging of dopamine D/receptors in the human cortex with [(1)(1)C]FLB 457: reproducibility studies. Synapse 65 (1):35-40
115. Aalto S et al (2009) The effects of damphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11 C] FLB 457 in healthy subjects. Eur J Nucl Med Mol Imaging 36(3):475-83
116. Montgomery AJ et al (2007) Measurement of methylphenidate-induced change in extrastriatal dopamine concentration using [11 C]FLB 457 PET. J Cereb Blood Flow Metab 27(2):369-77
117. Frankle WG et al (2010) No effect of dopamine depletion on the binding of the highaffinity D 2/3 radiotracer [11 C]FLB 457 in the human cortex. Synapse 64(12):879-85
118. Riccardi P et al (2008) Estimation of baseline dopamine D2 receptor occupancy in striatum and extrastriatal regions in humans with positron emission tomography with [18 F] fallypride. Biol Psychiatry 63(2):241-4
119. Willeit M et al (2008) First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: a [11 C]-(+)- PHNO positron emission tomography study. Neuropsychopharmacology 33(2):279-89
120. Shotbolt P, et al. (2012) Within-subject comparison of [11 C]-(+)-PHNO and [11 C]Raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cereb Blood Flow Metab 32:127-136
121. Laruelle M et al (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects. Proc Natl Acad Sci USA 93:9235-9240
122. Abi-Dargham A et al (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761-767
123. Laruelle M et al (1999) Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46(1):56-72
124. Abi-Dargham A et al (2004) Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry 55(10):1001-6
125. Kegeles LS et al (2000) Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 48(7):627-640
126. Laruelle M, Kegeles LS, Abi-Dargham A (2003) Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci 1003:138-158
127. Kegeles LS et al (2010) Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18 F]fallypride positron emission tomography. Biol Psychiatry 68(7):634-41
128. Volkow ND et al (1997) Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386:830-833
129. Malison RT, Mechanic KY, Klummp HEA (1999) Reduced amphetamine-stimulated dopamine release in cocaine addicts as measured by [123I]IBZM SPECT. J Nucl Med 40:110P
130. Martinez D et al (2007) Amphetamineinduced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry 164(4):622-9
131. Martinez D et al (2009) Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. Am J Psychiatry 166(10):1170-7
132. Volkow ND et al (2007) Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement. J Neurosci 27(46):12700-6
133. Martinez D et al (2005) Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry 58 (10):779-86
134. Busto UE et al (2009) Dopaminergic activity in depressed smokers: a positron emission tomography study. Synapse 63(8):681-9
135. Martinez D, Narendran R (2010) Imaging neurotransmitter release by drugs of abuse. Curr Top Behav Neurosci 3:219-45
136. Piccini P, Pavese N, Brooks DJ (2003) Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann Neurol 53(5):647-53
137. Koochesfahani KM et al (2006) Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies. Mov Disord 21 (7):970-5
138. Volkow ND et al (2007) Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attentiondeficit/ hyperactivity disorder. Arch Gen Psychiatry 64(8):932-40
139. Singer HS et al (2002) Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry 159 (8):1329-36
140. Parsey RVet al (2001) Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry 50(5):313-22
141. Schneier FR et al (2000) Low dopamine D(2) receptor binding potential in social phobia. Am J Psychiatry 157(3):457-459
142. Wang GJ et al (2011) Enhanced striatal dopamine release during food stimulation in binge eating disorder. Obesity (Silver Spring) 19 (8):1601-8
143. Bailer UF et al (2011) Amphetamine induced dopamine release increases anxiety in individuals recovered from anorexia nervosa. Int J Eat Disord 45:263-71
144. Riccardi P et al (2010) Sex differences in the relationship of regional dopamine release to affect and cognitive function in striatal and extrastriatal regions using positron emission tomography and [(1)F]fallypride. Synapse 65 (2):99-102
145. Egerton A et al (2009) The dopaminergic basis of human behaviors: a review of molecular imaging studies. Neurosci Biobehav Rev 33(7):1109-32
146. Slifstein M, Laruelle M (2001) Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol 28 (5):595-608
147. Guo Q, Brady M, Gunn RN (2009) A biomathematical modeling approach to central nervous system radioligand discovery and development. J Nucl Med 50(10):1715-23
148. Laruelle M, Slifstein M, Huang Y (2003) Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol 5(6):363-75
149. Seeman P, Guan H-C, Niznik HB (1989) Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3 H] raclopride: implications for positron emission tomography of the human brain. Synapse 3:96-97
150. Cheng Y, Prusoff W (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
151. Sulzer D et al (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15(5 Pt 2):4102-8
152. Fischer JF, Cho AK (1979) Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther 208(2):203-9
153. Raiteri M et al (1979) Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J Pharmacol Exp Ther 208 (2):195-202
154. Parker EM, Cubeddu LX (1986) Effects of damphetamine and dopamine synthesis inhibitors on dopamine and acetylcholine neurotransmission in the striatum. I. Release in the absence of vesicular transmitter stores. J Pharmacol Exp Ther 237(1):179-92
155. Simon JR et al (1991) In vitro release of endogenous dopamine from the striatum of the weaver mutant mouse. J Neurochem 57 (5):1478-82
156. Butcher SP et al (1988) Amphetamineinduced dopamine release in rat striatum: an in vivo microdialysis study. J Neurochem 50:346-355
157. Connor CE, Kuczenski R (1986) Evidence that amphetamine and Na + gradient reversal increase striatal synaptosomal dopamine synthesis through carrier-mediated efflux of dopamine. Biochem Pharmacol 35 (18):3123-30
158. Nash JF, Yamamoto BK (1993) Effect of D-amphetamine on the extracellular concentrations of glutamate and dopamine in iprindole-treated rats. Brain Res 627(1):1-8
159. Cadoni C et al (1995) Role of vesicular dopamine in the in vivo stimulation of striatal dopamine transmission by amphetamine: evidence from microdialysis and Fos immunohistochemistry. Neuroscience 65 (4):1027-39
160. Sulzer D, Maidment NT, Rayport S (1993) Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J Neurochem 60 (2):527-35
161. Pifl C et al (1995) Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol Pharmacol 47(2):368-373
162. Florin SM, Kuczenski R, Segal DS (1995) Effects of reserpine on extracellular caudate dopamine and hippocampus norepinephrine responses to amphetamine and cocaine: mechanistic and behavioral considerations. J Pharmacol Exp Ther 274(1):231-41
163. Dluzen DE, Liu B (1994) The effect of reserpine treatment in vivo upon L-dopa and amphetamine evoked dopamine and DOPAC efflux in vitro from the corpus striatum of male rats. J Neural Transm Gen Sect 95(3):209-22
164. Schiffer WK et al (2006) Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse 59(4):243-51
165. Sibley DR, De Lean A, Creese I (1982) Anterior pituitary receptors: demonstration of interconvertible high and low affinity states of the D2 dopamine receptor. J Biol Chem 257:6351-6361
166. Seeman P, Grigoriadis D (1987) Dopamine receptors in brain and periphery. Neurochem Int 10:1-25
167. Richfield EK, Penney JB, Young AB (1989) Anatomical and affinity state comparisons between dopamine D1 and D2 receptors in the rat central nervous system. Neuroscience 30(3):767-77
168. Zahniser NR, Molinoff PB (1978) Effect of guanine nucleotides on striatal dopamine receptors. Nature 275(5679):453-5
169. George SR et al (1985) The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology 117(2):690-7
170. Caille I, Dumartin B, Bloch B (1996) Ultrastructural localization of D1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervation. Brain Res 730(1-2):17-31
171. Levey AI et al (1993) Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci USA 90(19):8861-5
172. Smiley JF et al (1994) D1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: predominant and extrasynaptic localization in dendritic spines. Proc Natl Acad Sci USA 91(12):5720-4
173. Hersch SM et al (1995) Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J Neurosci 15(7 Pt 2):5222-37
174. Yung KK et al (1995) Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 65 (3):709-30
175. Church WH, Justice JB, Byrd LD (1987) Extracellular dopamine in rat striatum following uptake inhibition by cocaine, nomifensine and benztropine. Eur J Pharmacol 139:345-348
176. Kawagoe KT et al (1992) Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum. Neuroscience 51 (1):55-64
177. May LJ (1988) Differentiation of dopamine overflow and uptake processes in the extracellular fluid of the rat caudate nucleus with fastscan in vivo voltammetry. J Neurochem 51 (4):1060-1069
178. Grace AA (1993) Cortical regulation of subcortical systems and its possible relevance to schizophrenia. J Neural Transm 91:111-134
179. Kuhr WG et al (1984) Monitoring the stimulated release of dopamine with in vivo voltammetry. I: Characterization of the response observed in the caudate nucleus of the rat. J Neurochem 43(2):560-9
180. Kuhr WG, Wightman RM (1986) Real-time measurement of dopamine release in rat brain. Brain Res 381(1):168-71
181. Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41(1):1-24
182. Kim SE et al (1998) Nicotine-induced dopamine release evaluated with in vivo 3 H raclopride binding studies: comparison with in vivo dialysis data. J Nucl Med 39:54P
183. Tsukada H et al (1999) Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [11 C]raclopride?: PET studies combined with microdialysis in conscious monkeys. Brain Res 841 (1-2):160-9
184. Richfield EK, Penney JB, Young AB (1989) Anatomical and affinity state comparisons between dopamine D1 and D2 reseptors in the rat central nervous system. Neuroscience 30(3):767-777
185. Drevets WC et al (1999) PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum. Neuropsychopharmacology 21(6):694-709
186. Endres CJ et al (1997) Kineticmodeling of [C- 11]raclopride: Combined PET-microdialysis studies. J Cereb Blood Flow Metab 17 (9):932-942
187. Seeman P (1993) Receptor tables. Vol. 2: Drug dissociation constants for neuroreceptors and transporters. Toronto, Canada
188. Richfield EK, Young AB, Penney JB (1986) Properties of D2 dopamine receptor autoradiography: high percentage of high-affinity agonist sites and increased nucleotide sensitivity in tissue sections. Brain Res 383 (1-2):121-8
189. Rabiner EA et al (2009) In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in nonhuman primates and transgenic mice. Synapse 63(9):782-93
190. Tziortzi AC et al (2011) Imaging dopamine receptors in humans with [(11)C]-(+)- PHNO: dissection of D3 signal and anatomy. Neuroimage 54:264-77
191. Searle G et al (2010) Imaging dopamine D(3) receptors in the human brain with positron emission tomography, [(11)C]PHNO, and a selective D(3) receptor antagonist. Biol Psychiatry 68:392-399
192. Sokoloff P et al (1992) Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. Eur J Pharmacol 225(4):331-7
193. Narendran R et al (2007) Amphetamineinduced dopamine release: duration of action as assessed with the D2/3 receptor agonist radiotracer (-)-N-[(11)C]propyl-norapomorphine ([11 C]NPA) in an anesthetized nonhuman primate. Synapse 61(2):106-9
194. Green AL, El Haut MJ (1978) Inhibition of mouse brain monoamine oxidase by (+) amphetamine in vivo. J Pharm Pharmacol 30:262-263
195. Uretsky NJ, Snodgrass SR (1977) Studies on the mechanism of stimulation of dopamine synthesis by amphetamine in striatal slices. J Pharmacol Exp Ther 202:565-580
196. Grady EF, Bohm SK, Bunnett NW (1997) Turning off the signal: mechanisms that attenuate signaling by G protein-coupled receptors. Am J Physiol 273(3 Pt 1): G586-601
197. Koenig JA, Edwardson JM (1997) Endocytosis and recycling of G protein-coupled receptors. Trends Pharmacol Sci 18(8):276-87
198. Feger J, Gil-Falgon S, Lamaze C (1994) Cell receptors: definition, mechanisms and regulation of receptor- mediated endocytosis. Cell Mol Biol (Noisy-le-grand) 40(8):1039-61
199. Sternini C et al (1996) Agonist-selective endocytosis of mu opioid receptor by neurons in vivo. Proc Natl Acad Sci USA 93 (17):9241-6
200. Fonseca MI, Button DC, Brown RD (1995) Agonist regulation of alpha 1B-adrenergic receptor subcellular distribution and function. J Biol Chem 270(15):8902-9
201. Barak LS et al (1997) Internal trafficking and surface mobility of a functionally intact beta2- adrenergic receptor-green fluorescent protein conjugate. Mol Pharmacol 51(2):177-84
202. Roettger BF et al (1995) Dual pathways of internalization of the cholecystokinin receptor. J Cell Biol 128(6):1029-41
203. Mantyh PWet al (1995) Rapid endocytosis of a G protein-coupled receptor: substance P evoked internalization of its receptor in the rat striatum in vivo. Proc Natl Acad Sci USA 92(7):2622-6
204. Faure MP et al (1995) Somatodendritic internalization and perinuclear targeting of neurotensin in the mammalian brain. J Neurosci 15 (6):4140-7
205. Roth BL et al (1998) 5-Hydroxytryptamine2- family receptors (5-hydroxytryptamine2A, 5- hydroxytryptamine2B,5-hydroxytryptamine2C): where structure meets function. Pharmacol Ther 79(3):231-57
206. Maloteaux JM, Hermans E (1994) Agonistinduced muscarinic cholinergic receptor internalization, recycling and degradation in cultured neuronal cells. Cellular mechanisms and role in desensitization. Biochem Pharmacol 47(1):77-88
207. Grady CL et al (1993) Activation of cerebral blood flow during a visuoperceptual task in patients with Alzheimer-type dementia. Neurobiol Aging 14(1):35-44
208. Barbier P et al (1997) Pergolide binds tightly to dopamine D2 short receptors and induces receptor sequestration. J Neural Transm 104 (8-9):867-74
209. Itokawa M et al (1996) Sequestration of the short and long isoforms of dopamine D2 receptors expressed in Chinese hamster ovary cells. Mol Pharmacol 49(3):560-6
210. Ng GY et al (1997) Resistance of the dopamine D2L receptor to desensitization accompanies the up-regulation of receptors on to the surface of Sf9 cells. Endocrinology 138 (10):4199-206
211. Barton AC, Black LE, Sibley DR (1991) Agonist-induced desensitization of D2 dopamine receptors in human Y-79 retinoblastoma cells. Mol Pharmacol 39(5):650-658
212. Vickery RG, von Zastrow M (1999) Distinct dynamin-dependent and -independent mechanisms target structurally homologous dopamine receptors to different endocytic membranes. J Cell Biol 144(1):31-43
213. Iwata K et al (1999) Dynamin and rab5 regulate GRK2-dependent internalization of dopamine D2 receptors. Eur J Biochem 263 (2):596-602
214. Ito K et al (1999) Sequestration of dopamine D2 receptors depends on coexpression of Gprotein- coupled receptor kinases 2 or 5. Eur J Biochem 260(1):112-9
215. Ko F et al (2002) Dopamine D2 receptors internalize in their low-affinity state. Neuroreport 13(8):1017-20
216. Namkung Y, Sibley DR (2004) Protein kinase C mediates phosphorylation, desensitization, and trafficking of the D2 dopamine receptor. J Biol Chem 279(47):49533-41
217. Paspalas CD, Rakic P, Goldman-Rakic PS (2006) Internalization of D2 dopamine receptors is clathrin-dependent and select to dendro-axonic appositions in primate prefrontal cortex. Eur J Neurosci 24 (5):1395-403
218. Goggi JL et al (2007) Agonist-dependent internalization of D2 receptors: imaging quantification by confocal microscopy. Synapse 61(4):231-41
219. Celver J, Sharma M, Kovoor A (2010) RGS9- 2 mediates specific inhibition of agonistinduced internalization of D2-dopamine receptors. J Neurochem 114(3):739-49
220. Sun W et al (2003) In vivo evidence for dopamine-mediated internalization of D2- receptors after amphetamine: differential findings with [3 H]raclopride versus [3 H] spiperone. Mol Pharmacol 63(2):456-62
221. Chugani DC, Ackermann RF, Phelps ME (1988) In vivo [3 H]spiperone binding: evidence for accumulation in corpus striatum by agonist-mediated receptor internalization. J Cereb Blood Flow Metab 8(3):291-303
222. Guo N et al (2009) Impact of D2 receptor internalization on binding affinity of neuroimaging radiotracers. Neuropsychopharmacology 35(3):806-17
223. SkinbjergMet al (2010) D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalizationdeficient mouse model. Neuroimage 50 (4):1402-7
224. Skinbjerg M et al (2009) Pharmacological characterization of 2-methoxy-N-propylnorapomorphine's interactions with D2 and D3 dopamine receptors. Synapse 63(6):462-75
225. Chou YH et al (1999) A PET study of D1-like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain. Psychopharmacology 146:220-227
226. Dumartin B et al (1998) Internalization of D1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists. J Neurosci 18(5):1650-61
227. Ann X, Lewis DA, Sesack SR (1998) Ultrastructural localization of dopamine D1 or D2 receptor immunoreactivity in structures postsynaptic to tyrosine hydroxyalse-positive terminals in the monkey striataum. Soc Neurosci Abst 24:857
228. Paterson LM et al (2010) Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J Cereb Blood Flow Metab 30(10):1682-706
229. Finnema SJ et al (2010) Fenfluramineinduced serotonin release decreases [11 C] AZ10419369 binding to 5-HT1B-receptors in the primate brain. Synapse 64(7):573-7
230. Ridler K et al (2011) Characterization of in vivo pharmacological properties and sensitivity to endogenous serotonin of [(11) C] P943: a positron emission tomography study in Papio anubis. Synapse 65:1119-27
231. Cosgrove KP et al (2011) Assessing the sensitivity of [(11) C]p943, a novel 5-HT(IB) radioligand, to endogenous serotonin release. Synapse 65:1113-7
232. Love TM, Stohler CS, Zubieta JK (2009) Positron emission tomography measures of endogenous opioid neurotransmission and impulsiveness traits in humans. Arch Gen Psychiatry 66(10):1124-34
233. Zubieta JK et al (2001) Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 293 (5528):311-5
234. Zubieta JK et al (2003) COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299 (5610):1240-3
235. Ding YS et al (1998) Dopamine D2 receptor mediated regulation of central cholinergic activity: PET studies with [18 F]fluoroepibatidine. J Nucl Med 39:12P
236. Skaddan MB et al (2001) Acetylcholinesterase inhibition increases in vivo N-(2-[18 F]fluoroethyl)- 4-piperidyl benzilate binding to muscarinic acetylcholine receptors. J Cereb Blood Flow Metab 21(2):144-8
237. Skaddan MB et al (2002) (R)-N-[11 C] methyl-3-pyrrolidyl benzilate, a high-affinity reversible radioligand for PET studies of the muscarinic acetylcholine receptor. Synapse 45 (1):31-7
238. Ma B et al (2004) Sensitivity of [11 C]Nmethylpyrrolidinyl benzilate ([11 C] NMPYB) to endogenous acetylcholine: PET imaging vs tissue sampling methods. Nucl Med Biol 31(4):393-7
239. Kilbourn MR et al (2007) Anesthesia increases in vivo N-([18 F]fluoroethyl)piperidinyl benzilate binding to the muscarinic cholinergic receptor. Nucl Med Biol 34 (5):479-82
240. Frankle WG et al (2009) Tiagabine increases [11 C]flumazenil binding in cortical brain regions in healthy control subjects. Neuropsychopharmacology 34(3):624-33
241. Miyake N et al (2011) Imaging changes in glutamate transmission in vivo with the metabotropic glutamate receptor 5 tracer [11 C] ABP688 and N-acetylcysteine challenge. Biol Psychiatry 69(9):822-4
242. Narendran R et al (2011) Evaluation of dopamine D(2/3) specific binding in the cerebellum for the positron emission tomography radiotracer [(11) C]FLB 457: implications for measuring cortical dopamine release. Synapse 65:991-7
243. Xiao MF et al (2009) Neural cell adhesion molecule modulates dopaminergic signaling and behavior by regulating dopamine D2 receptor internalization. J Neurosci 29 (47):14752-63
244. Souza BR et al (2008) DARPP-32 and NCS- 1 expression is not altered in brains of rats treated with typical or atypical antipsychotics. Neurochem Res 33(3):533-8
245. Iizuka Y et al (2007) Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization. J Neurosci 27 (45):12390-5
246. Kung HF et al (1988) Dopamine D-2- receptor imaging radiopharmaceuticals: Synthesis, radiolabeling, and in vitro binding of R-(+)- and S-(-)-3-iodo-2-hydroxy-6- methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl] benzamide. J Med Chem 31:1039-1043
247. Slifstein M et al (2004) In vivo affinity of [18 F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. Psychopharmacology (Berl) 175 (3):274-86
248. Halldin C et al (1995) Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 36(7):1275-81
249. Seeman P et al (1985) Dopamine D2 receptor binding sites for agonists. A tetrahedral model. Mol Pharmacol 28(5):391-9
250. Seeman P et al (2005) Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors. Synapse 58(2):122-8